Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Wednesday, February 24, 2021 8:00:03 AM
https://finance.yahoo.com/news/cannbit-subsidiary-tikun-olam-cannbit-091500807.html
Collaboration to combine the cannabis expertise of both parties, including extensive clinical and related data of Cannbit and leading computational predictive biology capabilities and genomic data of Canonic
TEL AVIV and REHOVOT, Israel, Feb. 24, 2021 /PRNewswire/ -- Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. (TASE: TKUN), a leading medical cannabis company, and Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), focused on the development of medical cannabis products, today announced that they have entered into a collaboration agreement for the development of novel medical cannabis products.
Cannabis is known to contain hundreds of active compounds, and a critical need in the medical cannabis industry today is to connect specific active compounds to the relevant medical indication and to develop cannabis strains and products that include these specific active compounds in a stable and consistent manner. Many companies and research centers are attempting to address this challenge, but to date only limited success has been reported. Cannbit and Canonic believe that integrating their complementary cannabis expertise and data will be a significant and unique advantage in providing a solution to this challenge.
The companies expect that a combination of Cannbit's vast clinical data with respect to the impact of medical cannabis strains over many years, together with Canonic's recognized leading computational biology platform and cannabis breeding capabilities, will lead the companies to successful joint development of the target products. The development of the new products will be performed at Canonic's R&D facility and will be based on cannabis strains that both companies will contribute to the collaboration.
According to the agreement, each company will have full commercial rights to the products arising from the collaboration, and there will be cross royalties by each to the other company. It is the intention of the parties that the collaboration will be performed according to a work plan to be agreed upon by the parties and which will serve as the basis for an agreement that will cover the development program. Additional financial terms of the collaboration were not disclosed.
Mr. Avinoam Sapir, CEO of Tikun Olam-Cannbit stated: "Combining the synergistic capabilities of Canonic and Cannbit should provide a substantial competitive advantage with respect to both timing and quality of results. We are proud to partner with Canonic, a leader in the cannabis breeding field and computational genomics. The agreement is an important step in Tikun Olam-Cannbit's strategic growth and builds on other recently signed significant agreements."
Dr. Arnon Heyman, CEO of Canonic stated: "We enthusiastically look forward to this collaboration with Cannbit, a leading medical cannabis company with substantial commercial experience and clinical data. Representing an important part of our "Precise" product program, we are confident that this combination of complementary capabilities and technologies is unique in the cannabis field and look forward to reporting our progress."
About Tikun Olam-Cannbit Ltd.:
Founded in 2006, Tikun Olam was acquired by Cannbit Pharmaceuticals in 2019. Today, Tikun Olam-Cannbit is Israel's leading medical cannabis brand, with a unique ecosystem that adds value through the chain – from growth, cultivation and manufacturing to distribution, clinical research, training and patient care. Tikun Olam-Cannbit has accumulated vast knowledge and expertise in the field of medical cannabis, developing more than 42 award-winning proprietary strains, 4 licensed IPS, as well as 36 clinical and preclinical studies conducted in collaboration with leading doctors, hospitals and universities in Israel. For more information: https://tikun-olam.org.il/en
About Canonic Ltd.:
Canonic is a subsidiary of Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), developing medical cannabis products through a Computational Predictive Biology (CPB) platform. The company's products in development are aimed at improving active compounds yield, genetic stability and cannabis strains for specific medical indications. The company's strategy includes the development of cannabis strains in order to commercialize medical cannabis products independently or through collaborations. Canonic has exclusive access to Evogene's genomic assets and technology for the development of medical cannabis products. For more information, please visit: https://www.canonicbio.com/.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., seed traits through the Ag-Seeds division, and ag-solutions for castor oil production through Casterra Ltd. For more information, please visit: www.evogene.com.
Recent EVGN News
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 09/19/2024 08:15:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/17/2024 11:00:12 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 08:01:22 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 09/04/2024 11:00:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/26/2024 01:30:23 PM
- Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement • PR Newswire (US) • 08/23/2024 12:55:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/23/2024 12:50:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/22/2024 11:00:28 AM
- Evogene Reports Second Quarter 2024 Financial Results • PR Newswire (US) • 08/22/2024 11:00:00 AM
- Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule • PR Newswire (US) • 08/12/2024 11:11:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/12/2024 11:01:49 AM
- Evogene Schedules Second Quarter 2024 Financial Results Release • PR Newswire (US) • 08/12/2024 11:00:00 AM
- Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil • PR Newswire (US) • 07/31/2024 11:00:00 AM
- Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split • PR Newswire (US) • 07/23/2024 12:48:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/23/2024 11:00:10 AM
- ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants • PR Newswire (US) • 07/17/2024 12:00:00 PM
- Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat • PR Newswire (US) • 07/02/2024 11:00:00 AM
- Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country • PR Newswire (US) • 06/25/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/17/2024 08:10:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/06/2024 08:02:44 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/23/2024 03:00:08 PM
- Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma • PR Newswire (US) • 05/23/2024 03:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/23/2024 11:00:23 AM
- Evogene Reports First Quarter 2024 Financial Results • PR Newswire (US) • 05/23/2024 11:00:00 AM
- Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds • PR Newswire (US) • 05/21/2024 11:03:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM